News

New Patent for Caretaker Medical

Caretaker Medical has received issuance of a new Patent by the United States Patent and Trademark Office (USPTO) for self-calibrating systems for blood pressure wave form analysis and diagnostics, U.S. Patent No. 11,207,034, further strengthening the Company’s intellectual property position and coverage for the Company’s medical-grade continuous digital blood pressure and vital sign monitoring system.

“We are pleased to announce this new patent that is especially important for patient care as it enables ultra-fast, 30-second auto-calibration of arterial blood pressure, which is an essential measurement for cardiovascular health. This provides a big advantage over existing continuous blood pressure monitoring systems that require additional arm cuff calibration measurements, which add costly delays to set up time and patient care,” commented Jeff Pompeo, President and Chief Executive Officer of Caretaker Medical.

Caretaker Medical, a pioneer in wireless “beat-by-beat” hemodynamic monitoring technology, now has six issued patents in the U.S., Europe, and Asia, adding to the long-term value of our medical-grade VitalStream™ continuous patient monitoring system.

Learn more about Caretaker Medical here.

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by